The FDA has approved Emblaveo (Abbvie), an intravenously administered fixed-dose combination of the monobactam antibacterial drug aztreonam and the beta-lactamase inhibitor avibactam, for use with metronidazole to treat complicated intra-abdominal infections (cIAIs) in adults.
STANDARD TREATMENT — Complications of intra-abdominal infections such as cholecystitis and acute perforated appendicitis often include abscess formation and peritonitis. Infections are usually polymicrobial; typical pathogens include enteric gram-negative organisms (most commonly Escherichia coli, Klebsiella...
- A Treprostinil Inhaler (Yutrepia) for Pulmonary Hypertension
- Sebetralstat (Ekterly) for Treatment of Hereditary Angioedema Attacks
- In Brief: Label Changes for Menopausal Hormone Therapy Products
- In Brief: Removal of Suicidality Warning from GLP-1 Agonists for Weight Management
- Denileukin Diftitox (Lymphir) for Cutaneous T-Cell Lymphoma (online only)
- Sevabertinib (Hyrnuo) for NSCLC (online only)
ISSUE
Yutrepia (Liquidia), a dry powder inhaler formulation of the prostacyclin analog treprostinil, has been approved by the FDA to improve exercise ability in adults with pulmonary arterial hypertension (PAH; WHO Group 1) or pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3). Tyvaso DPI, another treprostinil dry powder inhaler, was approved earlier for the same indication.
PROSTACYCLIN AGONISTS — Prostacyclin analogs such as treprostinil cause vasodilation of pulmonary and systemic arterial beds and inhibit platelet aggregation. They have improved exercise ability in patients with pulmonary hypertension.1-3 Prostacyclin analogs and other prostacyclin agonists that are FDA-approved for treatment of PAH are listed in Table 2. Yutrepia, Tyvaso DPI, and treprostinil solution for nebulization (Tyvaso) are also …